GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » EV-to-FCF

Tenax Therapeutics (Tenax Therapeutics) EV-to-FCF : 0.38 (As of May. 12, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tenax Therapeutics's Enterprise Value is $-2.27 Mil. Tenax Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.90 Mil. Therefore, Tenax Therapeutics's EV-to-FCF for today is 0.38.

The historical rank and industry rank for Tenax Therapeutics's EV-to-FCF or its related term are showing as below:

TENX' s EV-to-FCF Range Over the Past 10 Years
Min: -11.4   Med: 1.07   Max: 1.37
Current: 0.38

During the past 13 years, the highest EV-to-FCF of Tenax Therapeutics was 1.37. The lowest was -11.40. And the median was 1.07.

TENX's EV-to-FCF is ranked better than
79.74% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs TENX: 0.38

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Tenax Therapeutics's stock price is $3.585. Tenax Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-34.240. Therefore, Tenax Therapeutics's PE Ratio for today is At Loss.


Tenax Therapeutics EV-to-FCF Historical Data

The historical data trend for Tenax Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics EV-to-FCF Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.56 -1.84 -1.93 -0.33 0.46

Tenax Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 0.37 0.77 0.60 0.46

Competitive Comparison of Tenax Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Tenax Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's EV-to-FCF falls into.



Tenax Therapeutics EV-to-FCF Calculation

Tenax Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-2.271/-5.904
=0.38

Tenax Therapeutics's current Enterprise Value is $-2.27 Mil.
Tenax Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tenax Therapeutics  (NAS:TENX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Tenax Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.585/-34.240
=At Loss

Tenax Therapeutics's share price for today is $3.585.
Tenax Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Tenax Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (Tenax Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502

Tenax Therapeutics (Tenax Therapeutics) Headlines

From GuruFocus

Tenax Therapeutics Provides 2023 Business Update

By sperokesalga sperokesalga 04-12-2023

Tenax Therapeutics Set to Join Russell Microcap� Index

By Business Wire Business Wire 06-10-2021

Tenax Therapeutics Announces Reverse Stock Split

By Stock market mentor Stock market mentor 01-04-2023